Chadwick Mills

Cooley advised Angitia Biopharmaceuticals, a clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for serious musculoskeletal diseases, on its $120 million Series C.

Cooley advised Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, on its up to $375 million in synthetic royalty and debt financings with Royalty Pharma and Pharmakon Advisors.

Cooley advised NGM Biopharmaceuticals (NGM Bio), a wholly owned subsidiary of NGM Bio Holdings and a privately held biotechnology company focused on discovering and developing transformative therapeutics for patients, on its $122 million Series A financing.

Cooley advised Acelyrin, INC., a late-stage biopharmaceutical company, in its $621 million initial public offering, the second-largest biotechnology IPO and largest clinical-stage biotechnology IPO ever.

Cooley advised Geron Corporation, a late-stage biopharmaceutical company in California pursuing therapies with the potential to extend and enrich the lives of patients living with hematologic malignancies, on its $227.8 million follow-on offering. Partners Chadwick Mills and Kristin VanderPas led the Cooley team.